{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T23:43:29Z","timestamp":1791848609975,"version":"4.3.4"},"reference-count":23,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2017,10,5]],"date-time":"2017-10-05T00:00:00Z","timestamp":1507161600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"GlaxoSmithKline Biologicals SA"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer Medicine"],"published-print":{"date-parts":[[2017,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Women remain at risk of human papillomavirus (<jats:styled-content style=\"fixed-case\">HPV<\/jats:styled-content>) infection for most of their lives. The duration of protection against <jats:styled-content style=\"fixed-case\">HPV<\/jats:styled-content>\u201016\/18 from prophylactic vaccination remains unknown. We investigated the 10\u2010year immune response and long\u2010term safety profile of the <jats:styled-content style=\"fixed-case\">HPV<\/jats:styled-content>\u201016\/18 <jats:styled-content style=\"fixed-case\">AS<\/jats:styled-content>04\u2010adjuvanted vaccine (<jats:styled-content style=\"fixed-case\">AS<\/jats:styled-content>04\u2010<jats:styled-content style=\"fixed-case\">HPV<\/jats:styled-content>\u201016\/18 vaccine) in females aged between 15 and 55\u00a0years at first vaccination. Females who received primary vaccination with three doses of <jats:styled-content style=\"fixed-case\">AS<\/jats:styled-content>04\u2010<jats:styled-content style=\"fixed-case\">HPV<\/jats:styled-content>\u201016\/18 vaccine in the primary phase\u2010<jats:styled-content style=\"fixed-case\">III<\/jats:styled-content> study (<jats:styled-content style=\"fixed-case\">NCT<\/jats:styled-content>00196937) were invited to attend annual evaluations for long\u2010term immunogenicity and safety. Anti\u2010<jats:styled-content style=\"fixed-case\">HPV<\/jats:styled-content>\u201016\/18 antibodies in serum and cervico\u2010vaginal secretions (<jats:styled-content style=\"fixed-case\">CVS<\/jats:styled-content>) were measured using enzyme\u2010linked immunosorbent assay (<jats:styled-content style=\"fixed-case\">ELISA<\/jats:styled-content>). Serious adverse events (<jats:styled-content style=\"fixed-case\">SAE<\/jats:styled-content>s) were recorded throughout the follow\u2010up period. Seropositivity rates for anti\u2010<jats:styled-content style=\"fixed-case\">HPV<\/jats:styled-content>\u201016 remained high (\u226596.3%) in all age groups 10\u00a0years after first vaccination. It was found that 99.2% of 15\u201325\u2010year olds remained seropositive for anti\u2010<jats:styled-content style=\"fixed-case\">HPV<\/jats:styled-content>\u201018 compared to 93.7% and 83.8% of 26\u201345\u2010year olds and 45\u201355\u2010year olds, respectively. Geometric mean titers (<jats:styled-content style=\"fixed-case\">GMT<\/jats:styled-content>) remained above natural infection levels in all age groups. Anti\u2010<jats:styled-content style=\"fixed-case\">HPV<\/jats:styled-content>\u201016 and anti\u2010<jats:styled-content style=\"fixed-case\">HPV<\/jats:styled-content>\u201018 titers were at least 5.3\u2010fold and 3.1\u2010fold higher than titers observed after natural infection, respectively, and were predicted to persist above natural infection levels for \u226530\u00a0years in all age groups. At Year 10, anti\u2010<jats:styled-content style=\"fixed-case\">HPV<\/jats:styled-content>\u201016\/18 antibody titers in subjects aged 15\u201325\u00a0years remained above plateau levels observed in previous studies. Correlation coefficients for antibody titers in serum and <jats:styled-content style=\"fixed-case\">CVS<\/jats:styled-content> were 0.64 (anti\u2010<jats:styled-content style=\"fixed-case\">HPV<\/jats:styled-content>\u201016) and 0.38 (anti\u2010<jats:styled-content style=\"fixed-case\">HPV<\/jats:styled-content>\u201018). This study concluded that vaccinated females aged 15\u201355\u00a0years elicited sustained immunogenicity with an acceptable safety profile up to 10\u00a0years after primary vaccination, suggesting long\u2010term protection against <jats:styled-content style=\"fixed-case\">HPV<\/jats:styled-content>.<\/jats:p>","DOI":"10.1002\/cam4.1155","type":"journal-article","created":{"date-parts":[[2017,10,6]],"date-time":"2017-10-06T04:06:41Z","timestamp":1507262801000},"page":"2723-2731","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":69,"title":["Ten\u2010year immune persistence and safety of the <scp>HPV<\/scp>\u201016\/18 <scp>AS<\/scp>04\u2010adjuvanted vaccine in females vaccinated at 15\u201355\u00a0years of age"],"prefix":"10.1002","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1505-1823","authenticated-orcid":false,"given":"Tino F.","family":"Schwarz","sequence":"first","affiliation":[{"name":"Central Laboratory and Vaccination Centre Klinikum W\u00fcrzburg Mitte Standort Juliusspital  W\u00fcrzburg Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrzej","family":"Galaj","sequence":"additional","affiliation":[{"name":"NZOZ Vitamed  Bydgoszcz Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marek","family":"Spaczynski","sequence":"additional","affiliation":[{"name":"Faculty of Medicine and Health Sciences University of Zielona Gora  Zielona Gora Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacek","family":"Wysocki","sequence":"additional","affiliation":[{"name":"Department of Preventive Medicine Poznan University of Medical Sciences  Poznan Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas M.","family":"Kaufmann","sequence":"additional","affiliation":[{"name":"Department of Gynecology Charit\u00e9\u2010Universit\u00e4tsmedizin Berlin  Berlin Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylviane","family":"Poncelet","sequence":"additional","affiliation":[{"name":"GSK  Rixensart Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pemmaraju V.","family":"Suryakiran","sequence":"additional","affiliation":[{"name":"GSK  Bangalore India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Folschweiller","sequence":"additional","affiliation":[{"name":"GSK  Wavre Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florence","family":"Thomas","sequence":"additional","affiliation":[{"name":"GSK  Wavre Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lan","family":"Lin","sequence":"additional","affiliation":[{"name":"GSK  Wavre Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Struyf","sequence":"additional","affiliation":[{"name":"GSK  Wavre Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2017,10,5]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F"},{"key":"e_1_2_9_3_1","unstructured":"ICO Information Centre on HPV and Cancer.Human Papillomavirus and Related Diseases Report \u2010 World [Published 2015]. Available from:http:\/\/hpvcentre.net\/statistics\/reports\/XWX.pdf. (accessed 12 January 2016)"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(10)70230-8"},{"key":"e_1_2_9_5_1","unstructured":"European Medicines Agency.EPAR summary for the public [Published 2014].Available from:http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Summary_for_the_public\/human\/000721\/WC500024634.pdf(accessed March 3 2016)"},{"key":"e_1_2_9_6_1","unstructured":"United States Food and Drug Administration.October 16 2009 Approval Letter \u2010 Cervarix [Published2009.Available from:http:\/\/www.fda.gov\/BiologicsBloodVaccines\/Vaccines\/ApprovedProducts\/ucm186959.htm.(accessedMarch 3 2016)"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2009.09.021"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2015.146"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.29971"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2008.10.088"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/1471-0528.13070"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(16)30120-7"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(04)17398-4"},{"key":"e_1_2_9_14_1","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1016\/S0140-6736(09)61567-1","article-title":"Sustained efficacy and immunogenicity of the human papillomavirus (HPV)\u201016\/18 AS04\u2010adjuvanted\u00a0vaccine: analysis of a randomised placebo\u2010controlled trial up to 6.4\u00a0years","volume":"374","author":"GlaxoSmithKline Vaccine HPV\u2010007 Study Group","year":"2009","journal-title":"Lancet"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.4161\/hv.29532"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)61248-4"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2010.07.007"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djg018"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.4161\/hv.6.12.13399"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2009.01.011"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0000000000000460"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1109\/TAC.1974.1100705"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)60946-5"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.25887"}],"container-title":["Cancer Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcam4.1155","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cam4.1155","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,26]],"date-time":"2023-09-26T09:36:20Z","timestamp":1695720980000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/cam4.1155"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10,5]]},"references-count":23,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2017,11]]}},"alternative-id":["10.1002\/cam4.1155"],"URL":"https:\/\/doi.org\/10.1002\/cam4.1155","archive":["Portico"],"relation":{},"ISSN":["2045-7634","2045-7634"],"issn-type":[{"value":"2045-7634","type":"print"},{"value":"2045-7634","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,10,5]]},"assertion":[{"value":"2017-02-16","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-07-07","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-10-05","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}